Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.61 +1.3%	$1.43	$1.05 ▼ $5.17	$172.17M	0.38	1.18 million shs	650,344 shs
AMTI Applied Molecular Transport	$0.26	$0.24	$0.13 ▼ $0.84	$10.87M	2.28	470,969 shs	N/A
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,076 shs	237,144 shs
OLMA Olema Pharmaceuticals	$4.41 -2.2%	$4.57	$2.86 ▼ $16.62	$308.58M	1.9	812,175 shs	287,496 shs
TBPH Theravance Biopharma	$11.25 -3.2%	$10.42	$7.44 ▼ $11.88	$581.02M	-0.02	257,811 shs	144,416 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.63%	0.00%	+13.57%	+39.47%	+20.45%
AMTI Applied Molecular Transport	0.00%	0.00%	0.00%	0.00%	0.00%
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+30.01%
OLMA Olema Pharmaceuticals	-1.10%	-7.01%	+12.47%	+2.04%	-68.75%
TBPH Theravance Biopharma	-0.26%	+1.40%	+9.62%	+34.80%	+17.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.2089 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	0.6
AMTI Applied Molecular Transport	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	0.2147 of 5 stars	0.0	0.0	0.0	4.2	0.0	0.8	0.0
OLMA Olema Pharmaceuticals	2.4645 of 5 stars	3.5	1.0	0.0	0.0	2.7	2.5	0.6
TBPH Theravance Biopharma	1.7195 of 5 stars	3.3	0.0	0.0	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	441.26% Upside
AMTI Applied Molecular Transport	0.00	N/A	N/A	N/A
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	455.56% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	47.56% Upside

Current Analyst Ratings Breakdown

Latest CARA, OLMA, TBPH, AMTI, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.31	N/A	N/A	$1.44 per share	1.12
AMTI Applied Molecular Transport	N/A	N/A	N/A	N/A	$1.56 per share	N/A
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
TBPH Theravance Biopharma	$64.38M	8.74	N/A	N/A	$3.57 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
AMTI Applied Molecular Transport	-$126.32M	-$1.90	N/A	N/A	N/A	N/A	-223.46%	-126.91%	N/A
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	0.00	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	32.14	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)

Latest CARA, OLMA, TBPH, AMTI, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/5/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	TBPH Theravance Biopharma	-$0.12	N/A	N/A	N/A	$16.04 million	N/A
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
AMTI Applied Molecular Transport	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
AMTI Applied Molecular Transport	N/A	4.99	4.99
CARA Cara Therapeutics	N/A	4.77	4.71
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
TBPH Theravance Biopharma	N/A	4.77	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
AMTI Applied Molecular Transport	41.79%
CARA Cara Therapeutics	44.66%
OLMA Olema Pharmaceuticals	91.78%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
AMTI Applied Molecular Transport	15.90%
CARA Cara Therapeutics	3.10%
OLMA Olema Pharmaceuticals	16.36%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
AMTI Applied Molecular Transport	13	41.34 million	34.76 million	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
TBPH Theravance Biopharma	110	50.00 million	46.55 million	Optionable

CARA, OLMA, TBPH, AMTI, and ACRS Headlines

Recent News About These Companies

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60

July 17 at 3:41 AM | americanbankingnews.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of Stock

July 16 at 7:18 PM | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16 at 10:05 AM | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen

July 14, 2025 | americanbankingnews.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Wall Street Zen

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

June 27, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

June 27, 2025 | marketbeat.com

TBPH Theravance Biopharma, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 26, 2025 | prnewswire.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" Rating

June 21, 2025 | marketbeat.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of Stock

June 5, 2025 | insidertrades.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

June 3, 2025 | zacks.com

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

June 2, 2025 | marketwatch.com

Theravance hands off the last of its Trelegy royalties to GSK for $225M

June 2, 2025 | fiercepharma.comF

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

June 2, 2025 | prnewswire.com

Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine

May 21, 2025 | investing.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

May 13, 2025 | prnewswire.com

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)

May 11, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, OLMA, TBPH, AMTI, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.61 +0.02 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 -0.05 (-3.11%)

As of 07:44 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Applied Molecular Transport NASDAQ:AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Olema Pharmaceuticals NASDAQ:OLMA

$4.41 -0.10 (-2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$4.42 +0.01 (+0.23%)

As of 04:11 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Theravance Biopharma NASDAQ:TBPH

$11.25 -0.37 (-3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$11.24 -0.01 (-0.09%)

As of 07:36 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time